[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-and-obese-volunteers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-and-obese-volunteers":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100553976","phase-1-evaluate-lae102-in-healthy-and-overweightobese-subjects-100553976",false,"NCT06493084","Evaluate LAE102 in Healthy and Overweight\u002FObese Subjects","A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LAE102 Injection in Healthy and Overweight\u002FObese Subjects","Inclusion Criteria:\n\n1. Male or female and aged 18 to 65 years (inclusive) at the screening visit\n2. Male Body weight ≥ 50 kg, female Body weight ≥ 45 kg. For Part A\\&B, 18.5 ≤ BMI ≤ 28 kg\u002Fm². For part C, 26.0 ≤ BMI ≤ 40.0 kg\u002Fm²\n3. Negative for human immunodeficiency virus antibody (HIV-Ab).\n4. Female subjects with no childbearing potential or with childbearing potential which serum human chorionic gonadotropin (hCG) test must \\\u003C5mIU\u002FmL .\n5. Male subjects are not allowed to donate sperm during this trial.\n6. Voluntarily participate in the study and provide a signed and dated informed consent form.\n7. Willing to comply with the scheduled visits, study treatment, laboratory tests, and other study-related procedures and requirements as stipulated in the study protocol.\n\nExclusion Criteria:\n\n1. With clinically significant abnormalities in vital signs, physical examination, ECG or laboratory test results specified in the protocol.\n2. Allergy to the investigational drug or its excipients, or a history of severe allergy (including any food or drug allergies).\n3. Self-reported weight change is more than 5% in the previous 3 months prior to screening.\n4. Diagnosed with secondary overweight or obesity.\n5. Any clinically significant medical conditions and any diseases affecting the safety of the subject or the determination of study results.\n6. History of major diseases or physical conditions in the central nervous system, respiratory system, cardiovascular system, digestive system, blood system, endocrine system, musculoskeletal diseases, mental illness, urinary system, or tumors, or any existing acute diseases, or other diseases or physical conditions that may affect the study or pose an unacceptable risk to the subjects.\n7. Positive for hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), or syphilis spirochete antibody (TP-Ab).\n8. Known or suspected history of substance abuse or positive drug screening test.\n9. Alcohol abuse within 1 year before screening or positive alcohol breath test at baseline.\n10. Smoking more than 5 cigarettes per day within 3 months before screening, or unable to comply with the prohibition of smoking during the study period.\n11. Received any vaccine within 30 days prior to screening, or planned to receive any vaccine during the study period.\n12. Inability to ensure no use of any drugs, including prescription and non-prescription drugs (excluding paracetamol, ibuprofen, and topically applied eye\u002Fnasal drops and ointments with no systemic exposure risk), vitamins, supplements and herbal medicines, from 14 days before the initial administration (if the half-life of the drug used exceeds 14 days, then 5 half-lives shall apply) until the last visit period.\n13. Participated in any clinical trial and received an investigational medicine or medical device within 3 months prior to dosing of the investigational product.\n14. Underwent major surgery within 30 days before the initial administration or planned to undergo major surgery during the study period.\n15. Donated blood or experienced blood loss ≥400 mL within 3 months before screening or received a blood transfusion.\n16. Have special dietary requirements and cannot comply with a standardized diet.\n17. History of fainting or syncope.\n18. Dieting or receiving weight loss treatment within 30 days before the initial administration or experiencing major changes in lifestyle.\n19. Use of GLP-1 receptor agonists, or weight loss medications or systemic corticosteroids (oral or intravenous for more than 7 days), or psychiatric medications within 3 months prior to the initial administration. Applicable to part C.\n20. Regular engaged in muscle strength related exercise, applicable to part C.\n21. Other situation that the investigator considers not appropriate.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight\u002Fobese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight\u002Fobese participants.",[28],"Overweight and Obese Volunteers","RECRUITING","2026-01-07",{"date":32,"type":33},"2026-01-09","ACTUAL",{"date":35,"type":33},"2024-06-25",{"date":37,"type":22},"2026-09-30",{"name":39,"class":40},"Laekna Limited","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100573367","weight-reduction-with-the-low-insulin-method---self-monitoring-of-breath-acetone-100573367","NCT06745362","Weight Reduction With the Low-Insulin-Method - Self Monitoring of Breath Acetone","WeR-LIM-SMBA","Inclusion Criteria:\n\n* Body Mass Index \\> 25kg\u002Fm2\n\nExclusion Criteria:\n\n\\-",{"count":50,"type":22},42,[52],"NA","The goal of this clinical trial is to learn if lifestyle intervention with information about ketosis state supports weight reduction in overweight adults.\n\nResearchers will compare an App-based lifestyle intervention with self-monitoring of breath acetone vs. lifestyle intervention alone.\n\nParticipants will:\n\nGet a lifestyle intervention via the LIM-App for 12 months. Report body weight.",[28],[56,57,58],"lifestyle intervention","weight reduction","ketosis","NOT_YET_RECRUITING","2025-06-25",{"date":62,"type":33},"2025-06-29",{"date":64,"type":22},"2026-01-01",{"date":66,"type":22},"2027-12-31",{"name":68,"class":69},"West German Center of Diabetes and Health","OTHER",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100575943","phase-1-a-phase-iiia-clinical-study-to-assess-the-single-and-multiple-ascending-doses-of-mdr-001-tablets-in-healthy-participants-and-obese-overweight-participants-100575943","NCT06778850","A Phase I\u002FIIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese\u002F Overweight Participants","A Randomized, Double-blind, Placebo-controlled Phase I\u002FIIa Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MDR-001 Tablets Administrated Orally in Healthy Participants and Obese\u002F Overweight Participants","Inclusion Criteria:\n\n* Participants who are aged ≥ 18 and ≤ 55 years at the time of signing the informed consent; no gender restriction.\n* Participants with 27 ≤ body mass index (BMI) ≤ 45 kg\u002Fm2.\n* For male participants, a waist circumference ≥ 90 cm is required, while female participants ≥ 85 cm.\n\nExclusion Criteria:\n\n* Participants with any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers.\n* Participants with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia 2 (MEN2), or those with hereditary diseases that easily induce to medullary thyroid carcinoma.\n* Participants with a history of pancreatitis or symptomatic gallbladder disease.\n* Serum calcitonin \\> ULN at screening.\n* Participants with systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg at screening.\n* Participants with ALT \\>2 × ULN and \u002For AST \\> 2 × ULN at screening.\n* Participants whose fasting triglycerides \\> 5.7 mmol\u002FL, total cholesterol \\> 7.75 mmol\u002FL, low-density lipoprotein cholesterol \\> 4.9 mmol\u002FL at screening.\n* Participants with abnormal uric acid levels accompanied by clinical symptoms (those without clinical symptoms can be included).\n* Participants with fasting blood glucose levels \\> 7 mmol\u002FL.\n* Participants with creatinine clearance \\\u003C 60 mL\u002Fmin at screening \\[calculation formula: CLcr: (140 - age) × weight (kg) \u002F \\[72 × 0.0113 × Scr (μmol\u002FL)\\], × 0.85 for females\\].\n* Participants have experienced significant changes in diet or exercise habits or within ≥5% changes in body weight within 3 months prior to screening.\n* Participants with clinically significant ECG abnormality deemed unsuitable participation for study by the investigator; or with ECG QTcF values \\> 450 ms for male participants or \\> 470 ms for female participants.","55 Years",{"count":79,"type":22},131,[25,81],"PHASE2","To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese\u002F overweight participants.",[28],"2025-03-05",{"date":86,"type":33},"2025-03-07",{"date":88,"type":33},"2023-06-09",{"date":90,"type":22},"2025-12-30",{"name":92,"class":40},"MindRank AI Ltd","Overweight and Obese Volunteers."]